Novavax (NVAX) FY2025 10-K Risk Factors: 24 New, 17 Dropped

What the changes say

Novavax faces significant execution risk regarding its reliance on Sanofi for commercialization and third parties for manufacturing.
Clinical development remains lengthy, expensive, and subject to high failure rates and unpredictable trial data.
Tax attribute utilization and potential net operating loss limitations create financial uncertainties for future taxable income.

What changed since the prior 10-K

New

NewRisks Related to Our Financial Condition and Capital Requirements
Limitations on the use of our net operating losses and other tax attributes could adversely affect our financial condition
Our federal and state net operating loss carryforwards of $2.6 billion and $842.1 million may expire or face deductibility limits.
NewRisks Related to Our Financial Condition and Capital Requirements
income (subject to any applicable limitations), if any. Our NOL carryforwards are subject to review and possible adjustment by the appropriate taxing authorities
Future cumulative ownership changes of more than 50 percentage points could limit our ability to use tax attributes under Sections 382 and 383.
NewRisks Related to Product Development and Commercialization
Clinical and preclinical development involves a lengthy and expensive process with an uncertain outcome, and the results of prior clinical trials are not necessarily predictive of our future results
Preclinical and clinical development is lengthy and expensive, and vaccine candidates can unexpectedly fail at any stage despite prior promising results.
NewRisks Related to Product Development and Commercialization
preclinical or clinical results, any vaccine candidate can unexpectedly fail at any stage of preclinical or clinical development. The historical failure rate for vaccine candidates in our industry is high, particularly in the early stages of development
Historical failure rates for vaccine candidates are high, and early preclinical or clinical results do not guarantee the success of later trials.
NewRisks Related to Product Development and Commercialization
Any difficulties or delays in the commencement or completion, or the termination or suspension, of our current or planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue or adversely affect our commercial prospects
Regulatory agencies like the FDA may require additional preclinical studies or clinical evaluations under our IND submissions, increasing costs and causing delays.
NewRisks Related to Product Development and Commercialization
We may find it difficult to enroll subjects in our clinical trials. If we encounter difficulties enrolling subjects in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
We may encounter difficulties identifying and enrolling a sufficient number of eligible subjects for our clinical trials, delaying development activities.
NewRisks Related to Product Development and Commercialization
We cannot assure you that our assumptions used in determining expected clinical trial timelines are correct or that we will not experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines
Adverse side effects or safety risks associated with our vaccine candidates could cause us to halt trials, abandon candidates, or restrict product labels.
NewRisks Related to Product Development and Commercialization
Interim, “topline” and preliminary data from our clinical trials and preclinical studies that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
Interim, topline, or preliminary clinical data are subject to audit and verification procedures, and final data may differ materially.
NewRisks Related to Product Development and Commercialization
preliminary data we previously published. As a result, topline and preliminary data should be viewed with caution until the final data are available
Regulatory agencies or competitors may interpret clinical data differently, impacting the approvability and commercial value of our vaccine candidates.
NewRisks Related to Product Development and Commercialization
In addition, regardless of any authorizations we have received supporting the development or commercialization of our vaccine candidates, unexpected safety issues could lead to product liability claims and our existing insurance may not be adequate for such claims
Unexpected safety issues could lead to product liability claims, and our existing insurance may be inadequate to cover them.
NewRisks Related to Our Dependence on Third Parties
We need to partner with a collaborator to handle marketing activities, and if we are unable to enter into collaborations with marketing partners, we may not be successful in commercializing any approved products
Because we transitioned commercialization of our COVID-19 Vaccine to Sanofi, our revenue depends entirely on the marketing efforts of third-party partners.
NewRisks Related to Our Dependence on Third Parties
authorization, these facilities must be authorized for the manufacture of our vaccine candidates in connection with any approval of any marketing application we submit
Complex biologic manufacturing processes are susceptible to contamination, equipment failure, and yield inconsistencies that can disrupt clinical trials and commercial supply.
NewRisks Related to Regulatory and Compliance Matters
The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our vaccine candidates, our business will be substantially harmed
NewRisks Related to Regulatory and Compliance Matters
The occurrence of any event or penalty described above may inhibit our ability to commercialize our vaccine candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity
NewRisks Related to Regulatory and Compliance Matters
Our vaccine candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated
NewRisks Related to our Intellectual Property
Our success depends on our ability to obtain, maintain, expand, enforce and defend the scope, ownership or control, and validity of intellectual property protections, to maintain the proprietary nature of our technology
NewRisks Related to our Intellectual Property
If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
NewRisks Related to our Intellectual Property
how or other proprietary information, and such risk has been enhanced by the departure of employees in connection with our global restructuring and cost reduction plan
NewRisks Related to our Intellectual Property
We may not be able to protect our intellectual property and proprietary rights throughout the world
NewRisks Related to our Intellectual Property
such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed.
NewRisks Related to our Intellectual Property
Intellectual property rights do not necessarily provide protection against all competitive harm to our business
NewRisks Related to Employee Matters, Managing Growth and Information Technology
Our global restructuring and cost reduction plans may disrupt our business
NewRisks Related to Our Indebtedness
Our Credit Agreement contains restrictions that limit our flexibility in operating our business
NewRisks Related to Our Indebtedness
in each case subject to customary exceptions and limitations

Dropped

DroppedRisks Related to Our Financial Condition and Capital Requirements
disruption or delay in the performance of our third-party contractors and suppliers. If such third parties are unable to adequately satisfy their contractual commitments to us in a timely manner, our business could be adversely affected
DroppedRisks Related to Product Development and Commercialization
competitors, these vaccine candidates prove less effective than competitors’ vaccines, or we are unable to successfully manufacture, distribute or market such vaccine candidates once approved, these shortcomings may lead to reputational harm, loss of market share, and adverse financial results
DroppedRisks Related to Product Development and Commercialization
Because we depend on third parties to conduct some of our laboratory testing and clinical trials, and a significant amount of our vaccine manufacturing and distribution, we may encounter delays in or lose some control over our efforts to develop and supply products
DroppedRisks Related to Product Development and Commercialization
If we are unable to effectively manufacture our COVID-19 Vaccine in sufficient quantities or at sufficient yields, we may experience delays or an adverse impact on product development, clinical trials, regulatory approvals and commercial distribution
Risks regarding disruptions from third-party contractors, collaboration agreements, and APAs.
DroppedRisks Related to Product Development and Commercialization
depend substantially on SII for co-formulation, filling, and finishing our COVID-19 Vaccine, and any delays or disruptions in these suppliers’ operations could prevent or delay the delivery of customer orders
DroppedRisks Related to Product Development and Commercialization
our product if sufficient amounts of our product are not available compared to that of our competitors or not procured by pharmacies or other providers
DroppedRisks Related to Product Development and Commercialization
We have limited marketing capabilities, and if we are unable to enter into collaborations with marketing partners or develop our own sales and marketing capability, we may not be successful in commercializing any approved products
Uncertainty surrounding 2025 revenue tied to the updated monovalent COVID-19 formulation under the Sanofi agreement.
DroppedRisks Related to Product Development and Commercialization
Our vaccine candidates could become subject to a product recall which could harm our reputation, business, and financial results
DroppedRisks Related to Regulatory and Compliance Matters
We may not succeed in obtaining full U.S. FDA licensure or foreign regulatory approvals necessary to sell our vaccine candidates
Dependence on third parties for laboratory testing, clinical trials, manufacturing, and distribution.
DroppedRisks Related to Regulatory and Compliance Matters
Our products might fail to meet their primary endpoints in clinical trials, meaning that we will not have the clinical data required to support regulatory approvals
DroppedRisks Related to Regulatory and Compliance Matters
We may fail to obtain regulatory approval for our prototype vaccine and for NVX-CoV2601 or for our other current or future product candidates on a timely basis or comply with our continuing regulatory obligations if approval is obtained
Risks of failing to manufacture COVID-19 vaccines in sufficient quantities and yields at commercial scale.
DroppedRisks Related to Regulatory and Compliance Matters
We expect that regulatory authorities will continue to monitor and assess SARS-CoV-2 evolution and recommend that manufacturers make corresponding updates to the composition of their COVID-19 vaccines at least annually
Dependence on SII for co-formulation, filling, and finishing of the COVID-19 vaccine.
DroppedRisks Related to Regulatory and Compliance Matters
The regulatory pathway for our COVID-19 Vaccine is continually evolving and may result in unexpected or unforeseen challenges
DroppedRisks Related to Regulatory and Compliance Matters
The later discovery of previously unknown problems with a product, manufacturer or facility may result in restrictions, including withdrawal of a vaccine that had previously received regulatory approval in certain jurisdictions from the market
DroppedRisks Related to Regulatory and Compliance Matters
Due to the recent change in presidential administration, we face uncertainty regarding potential regulatory developments that may adversely affect our business
Publicity and pricing pressure regarding pharmaceutical products in the industry.
DroppedRisks Related to our Intellectual Property
Our success depends on our ability to maintain the proprietary nature of our technology
Transitioning commercialization of the COVID-19 Vaccine to Sanofi for the 2025-2026 season.
DroppedRisks Related to Employee Matters, Managing Growth and Information Technology
Our announced global restructuring and cost reduction plans may not result in anticipated reductions in combined research and development and selling, general, and administrative expenses and may disrupt our business

Reworded

94% rewrittenRisks Related to Product Development and Commercialization
Fast Track Designation by the FDA may not actually lead to a faster development or regulatory review or approval process and does not assure approval
Added specific mention of Fast Track Designation granted for the R21/Matrix-M malaria vaccine alongside the influenza and prototype vaccines.
Was: Fast Track Designation by the U.S. FDA, the issue of conditional marketing authorizations by the EMA or MHRA, or other regulatory acceleration options may not actually lead to a faster development or regulatory review or approval process and does not assure approval
85% rewrittenRisks Related to Regulatory and Compliance Matters
Failure to obtain regulatory approval in foreign jurisdictions could prevent us from marketing our products internationally
Updated regulatory reference by removing foreign agency acronyms and changing 'FDA approval' references to match general U.S. standards.
Was: Failure to obtain regulatory approval in foreign jurisdictions would prevent us from marketing our products internationally
84% rewrittenRisks Related to our Intellectual Property
If we do not obtain patent term extension and/or patent term adjustment in the U.S. under the Hatch-Waxman Act and similar extensions in foreign countries, our ability to exclude competitors may be harmed
Refined patent lifespan discussion, replacing specific Hatch-Waxman Act details with broader language on patent expiration and commercialization risks.
83% rewrittenRisks Related to Our Financial Condition and Capital Requirements
Economic and political uncertainty may adversely affect our access to capital, cost of capital and ability to execute our business plan as scheduled
Maintained economic and geopolitical uncertainty disclosures regarding inflation, interest rates, and conflicts in Ukraine and the Middle East.
78% rewrittenRisks Related to Product Development and Commercialization
We may have product liability exposure
Updated product liability insurance coverage to specifically reference Nuvaxovid instead of listing multiple older trial programs.
76% rewrittenRisks Related to Product Development and Commercialization
Even if we successfully commercialize any of our vaccine candidates, either alone or in collaboration, we face uncertainty with respect to pricing, third-party reimbursement and healthcare reform, all of which could be subject to change and could adversely affect any commercial success of our vaccine candidates
Condensed third-party reimbursement and healthcare reform descriptions by removing bulleted lists of specific payer categories.
75% rewrittenRisks Related to Employee Matters, Managing Growth and Information Technology
Security breaches and other disruptions to our IT Systems or those of the vendors on whom we rely could compromise our information and expose us to liability, reputational damage, or other costs
Expanded IT systems and data privacy definitions, grouping customer, employee, and clinical participant data under 'Confidential Information'.
Was: Security breaches and other disruptions to our information technology systems or those of the vendors on whom we rely could compromise our information and expose us to liability, reputational damage, or other costs
74% rewrittenRisks Related to Product Development and Commercialization
Because our vaccine product development and commercialization efforts depend on new and rapidly evolving technologies, our efforts may not succeed
Removed specific references to past COVID-19 strains and manufacturing scale-up examples from the technology failure risk factor.
74% rewrittenRisks Related to Product Development and Commercialization
The emergence and transmissibility of variants of the SARS-CoV-2 virus may affect market acceptance or sales of our COVID-19 Vaccine
Was: The emergence and transmissibility of variants of the SARS-CoV-2 virus may affect market acceptance or sales of our COVID-19 Vaccine, and our strategy to develop new versions of our COVID-19 Vaccine to protect against certain variants may not be successful
72% rewrittenRisks Related to Our Indebtedness
Servicing our 4.625% Convertible Senior Notes due 2031 and our 5.00% Convertible Secured Notes due 2027 requires a significant amount of cash, and we may not have sufficient cash flow to pay our debt
Was: Servicing our 5.00% convertible senior unsecured notes due 2027 requires a significant amount of cash, and we may not have sufficient cash flow to pay our debt
67% rewrittenRisks Related to Our Dependence on Third Parties
We must identify vaccines for development with our technologies and establish successful third-party relationships
61% rewrittenRisks Related to Our Industry and Competition
There is significant competition in the development of a vaccine against COVID-19 and a combined vaccine against COVID-19 and influenza, and we may never see returns on the significant resources we have devoted and may continue to devote to our vaccine candidates
Was: There is significant competition in the development of a vaccine against COVID-19 and a combined vaccine against COVID-19 and influenza, and we may never see returns on the significant resources we are devoting to our vaccine candidates
34% rewrittenRisks Related to Our Financial Condition and Capital Requirements
We have a history of losses and our future profitability is uncertain
33% rewrittenRisks Related to Product Development and Commercialization
We are a biotechnology company and face significant risk in developing, manufacturing and commercializing our products
31% rewrittenRisks Related to Our Indebtedness
We may not have the ability to raise the funds necessary to repurchase the Notes as required upon a fundamental change, and our future debt may contain limitations on our ability to repurchase the Notes
27% rewrittenRisks Related to Product Development and Commercialization
We may not be able to secure sufficient supplies of a key component of our adjuvant technology

All 65 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Financial Condition and Capital Requirements

01We have a history of losses and our future profitability is uncertain34% rewritten
02We will continue to require significant funding to maintain our current level of operations and fund the further development of our vaccine candidates
03Economic and political uncertainty may adversely affect our access to capital, cost of capital and ability to execute our business plan as scheduled83% rewritten
04Limitations on the use of our net operating losses and other tax attributes could adversely affect our financial conditionNew
05income (subject to any applicable limitations), if any. Our NOL carryforwards are subject to review and possible adjustment by the appropriate taxing authoritiesNew

Risks Related to Product Development and Commercialization

06Because our vaccine product development and commercialization efforts depend on new and rapidly evolving technologies, our efforts may not succeed74% rewritten
07Clinical and preclinical development involves a lengthy and expensive process with an uncertain outcome, and the results of prior clinical trials are not necessarily predictive of our future resultsNew
08preclinical or clinical results, any vaccine candidate can unexpectedly fail at any stage of preclinical or clinical development. The historical failure rate for vaccine candidates in our industry is high, particularly in the early stages of developmentNew
09Any difficulties or delays in the commencement or completion, or the termination or suspension, of our current or planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue or adversely affect our commercial prospectsNew
10We may find it difficult to enroll subjects in our clinical trials. If we encounter difficulties enrolling subjects in our clinical trials, our clinical development activities could be delayed or otherwise adversely affectedNew
11We cannot assure you that our assumptions used in determining expected clinical trial timelines are correct or that we will not experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelinesNew
12Interim, “topline” and preliminary data from our clinical trials and preclinical studies that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final dataNew
13preliminary data we previously published. As a result, topline and preliminary data should be viewed with caution until the final data are availableNew
14The emergence and transmissibility of variants of the SARS-CoV-2 virus may affect market acceptance or sales of our COVID-19 Vaccine74% rewritten
15We are a biotechnology company and face significant risk in developing, manufacturing and commercializing our products33% rewritten
16We may have product liability exposure78% rewritten
17In addition, regardless of any authorizations we have received supporting the development or commercialization of our vaccine candidates, unexpected safety issues could lead to product liability claims and our existing insurance may not be adequate for such claimsNew
18Even if we successfully commercialize any of our vaccine candidates, either alone or in collaboration, we face uncertainty with respect to pricing, third-party reimbursement and healthcare reform, all of which could be subject to change and could adversely affect any commercial success of our vaccine candidates76% rewritten
19Our vaccine candidates may never achieve market acceptance even if we obtain regulatory approvals
20We may not be able to secure sufficient supplies of a key component of our adjuvant technology27% rewritten
21Our vaccine candidates are sensitive to shipping and storage conditions, which could subject our vaccine candidates to risk of loss or damage
22Fast Track Designation by the FDA may not actually lead to a faster development or regulatory review or approval process and does not assure approval94% rewritten

Risks Related to Our Dependence on Third Parties

23We need to partner with a collaborator to handle marketing activities, and if we are unable to enter into collaborations with marketing partners, we may not be successful in commercializing any approved productsNew
24Current or future regional relationships may hinder our ability to engage in larger transactions
25We must identify vaccines for development with our technologies and establish successful third-party relationships67% rewritten
26authorization, these facilities must be authorized for the manufacture of our vaccine candidates in connection with any approval of any marketing application we submitNew

Risks Related to Our Industry and Competition

27Many of our competitors have significantly greater resources and experience, which may negatively impact our commercial opportunities and those of our current and future licensees
28There is significant competition in the development of a vaccine against COVID-19 and a combined vaccine against COVID-19 and influenza, and we may never see returns on the significant resources we have devoted and may continue to devote to our vaccine candidates61% rewritten

Risks Related to Regulatory and Compliance Matters

29The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our vaccine candidates, our business will be substantially harmedNew
30The occurrence of any event or penalty described above may inhibit our ability to commercialize our vaccine candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicityNew
31Our vaccine candidates for which we intend to seek approval as biologic products may face competition sooner than anticipatedNew
32Failure to obtain regulatory approval in foreign jurisdictions could prevent us from marketing our products internationally85% rewritten
33Because we are subject to environmental, health and safety laws, we may be unable to conduct our business in the most advantageous manner
34For our vaccine candidates, we will be subject to additional healthcare laws and our failure to comply with those laws could have a material adverse effect on our results of operations and financial conditions

Risks Related to our Intellectual Property

35Our success depends on our ability to obtain, maintain, expand, enforce and defend the scope, ownership or control, and validity of intellectual property protections, to maintain the proprietary nature of our technologyNew
36If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmedNew
37how or other proprietary information, and such risk has been enhanced by the departure of employees in connection with our global restructuring and cost reduction planNew
38We may not be able to protect our intellectual property and proprietary rights throughout the worldNew
39Failure to obtain trademark registrations for proposed product names/brands, in the U.S. or abroad, may adversely impact our business
40Third parties may claim we infringe their intellectual property rights
41We may become involved in litigation to defend or enforce our intellectual property or the intellectual property of our collaborators or licensors, which could be expensive and time-consuming
42The scope, validity, and ownership of our patent claims may be challenged in various venues and, if we do not prevail, our ability to exclude competitors may be harmed, potentially reducing our ability to succeed commercially
43Even if we are ultimately successful, defending any such challenges may cause us to incur substantial expenses and may require us to divert substantial financial and management resources that we would otherwise be able to devote to our business
44We may need to license intellectual property from third parties and, if our right to use the intellectual property we license is affected, our ability to develop and outlicense our vaccine candidates may be harmed
45If patent laws or the interpretation of patent laws change, our competitors may be able to develop and commercialize our discoveries
46If we do not obtain patent term extension and/or patent term adjustment in the U.S. under the Hatch-Waxman Act and similar extensions in foreign countries, our ability to exclude competitors may be harmed84% rewritten
47such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed.New
48Intellectual property rights do not necessarily provide protection against all competitive harm to our businessNew

Risks Related to Employee Matters, Managing Growth and Information Technology

49Our business may be adversely affected if we do not successfully execute our business development initiatives
50Our global restructuring and cost reduction plans may disrupt our businessNew
51Security breaches and other disruptions to our IT Systems or those of the vendors on whom we rely could compromise our information and expose us to liability, reputational damage, or other costs75% rewritten
52Collaborations and contracts of our wholly owned subsidiary Novavax AB with partners such as Sanofi, with regional partners, such as SII, Takeda and SK bioscience, as well as with international providers, expose us to additional risks associated with doing business outside the U.S
53If we are unable to attract or retain key management or other personnel, our business, operating results and financial condition could be materially adversely affected

Risks Related to Our Indebtedness

54Servicing our 4.625% Convertible Senior Notes due 2031 and our 5.00% Convertible Secured Notes due 2027 requires a significant amount of cash, and we may not have sufficient cash flow to pay our debt72% rewritten
55We may not have the ability to raise the funds necessary to repurchase the Notes as required upon a fundamental change, and our future debt may contain limitations on our ability to repurchase the Notes31% rewritten
56Our Credit Agreement contains restrictions that limit our flexibility in operating our businessNew
57in each case subject to customary exceptions and limitationsNew

Risks Related to Ownership of Our Common Stock

58Because our stock price has been and will likely continue to be highly volatile, the market price of our common stock may be lower or more volatile than expected
59Raising additional capital by issuing securities or through collaboration and licensing arrangements may cause dilution to existing stockholders or require us to relinquish rights to our technologies or vaccine candidates
60Provisions of our Second Amended and Restated Certificate of Incorporation and Amended and Restated By-Laws and Delaware law could delay or prevent the acquisition of the Company, even if such acquisition would be beneficial to stockholders, and could impede changes in our Board
61We have never paid dividends on our capital stock, and we do not anticipate paying any such dividends in the foreseeable future
62Litigation or regulatory investigations could have a material adverse impact on our results of operation and financial condition
63We or the third parties upon whom we depend may be adversely affected by natural or man-made disasters or public health emergencies
64We are a target for public scrutiny, and our business may be impacted by unfavorable publicity
65The increasing use of social media platforms presents new risks and challenges to our business

Other Novavax 10-Ks

FY2024 10-K risk factors
58 risks
Novavax carries a $5.0 billion accumulated deficit and depends heavily on Sanofi and third-party contractors for vaccine manufacturing and commercialization. Regulatory approval timelines and the evolving nature of SARS-CoV-2 variants drive core business risks.
Filed Feb 27, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.